Core Viewpoint - The U.S. launch of PMI's Technovation platform represents a significant step towards advancing smoke-free alternatives and fostering collaboration among various stakeholders to promote a smoke-free future in the United States [2][4]. Group 1: Technovation Event - Technovation will debut on April 14, 2026, in Washington D.C., gathering experts, policymakers, and business leaders to discuss innovation and regulation in the smoke-free sector [1][4]. - The event aims to present new data on the U.S. adult smoking population and address challenges such as misconceptions about nicotine and the need for collaboration against illicit trade [4]. Group 2: PMI's Commitment and Investments - PMI has invested over $16 billion since 2008 in developing smoke-free products, which are now used by over 43 million legal-age consumers globally [5][8]. - The company is expanding its U.S. manufacturing capabilities, with facilities in Aurora, Colorado; Owensboro, Kentucky; and Wilson, North Carolina, and has grown its workforce from several hundred to over 3,000 employees [2][6]. Group 3: Smoke-Free Product Portfolio - PMI's smoke-free portfolio is anchored by ZYN, the leading smoke-free product in the U.S. and the first nicotine pouch authorized by the FDA [3][5]. - The smoke-free business accounted for 41.5% of PMI's total net revenues for the full year 2025, highlighting the company's focus on transitioning consumers to better alternatives [8]. Group 4: Regulatory and Market Position - PMI holds 80% of modified risk tobacco product authorizations and 41% of premarket tobacco product application marketing orders issued by the FDA, underscoring its leadership in scientific advancement and product innovation [5][8]. - The company is committed to responsible marketing practices and aims to provide approximately 30 million legal-age smokers with better smoke-free alternatives [6].

Summary of British American Tobacco (BAT) 2026 Conference Call Company Overview - **Company**: British American Tobacco (NYSE: BTI) - **Event**: 2026 Conference Call held on February 18, 2026 - **Key Speakers**: Tadeu Marroco (CEO), David Waterfield (President of Reynolds American) Core Industry Insights - **Transformation Goal**: BAT aims to become predominantly smokeless by 2035, focusing on a smoke-free future while maintaining organic growth and shareholder returns [2][3] - **Market Growth**: The nicotine industry is projected to grow at a 4% CAGR over the next five years, driven by double-digit growth in new categories like nicotine pouches, which are expected to nearly triple in revenue by 2030 [3][4] - **Consumer Behavior**: There is a significant shift as smokers transition to less risky alternatives, with polyuse (using multiple nicotine products) doubling over the last five years [4][5] Financial Performance - **Cash Flow**: BAT has generated strong free cash flow, allowing for substantial shareholder returns through dividends and share buybacks [1] - **Revenue Growth Targets**: BAT aims for 3%-5% revenue growth, 4%-6% adjusted profit from operations growth, and 5%-8% adjusted diluted EPS growth in the midterm [25] Product Categories - **Nicotine Pouches**: Fastest-growing category, with VELO being a leading brand. VELO's consumer numbers, volume, and revenue have tripled over the last three years [9][11] - **Vapor Products**: Vuse is the global leader with a 39% market share, and the category is expected to grow significantly as regulatory environments improve [13][14] - **Heated Products**: The glo product line is positioned in a growing market, with a focus on premium segments [15][16] Regulatory Environment - **Regulatory Progress**: There are now 24 countries with regulatory frameworks for nicotine pouches, up from 4 in 2022. The FDA has initiated a pilot program to expedite the approval process for nicotine pouches [12][38] - **Enforcement Actions**: Increased enforcement against illegal products is crucial for the vapor market, with significant progress noted in 2025 [37][38] U.S. Market Focus - **U.S. Strategy**: The U.S. is a cornerstone of BAT's strategy, with Reynolds American positioned to capitalize on the evolving market. The U.S. nicotine revenue pool is projected to grow above a 4% CAGR through 2030 [26][28] - **Investment Commitment**: BAT is committing GBP 2.5 billion by 2030 to support U.S. growth, which is expected to create over 2,000 jobs [30][31] Competitive Positioning - **Market Leadership**: Reynolds is the number one choice for adult nicotine consumers, with nearly 22 million users. The company has seen growth in all product categories, particularly in smokeless and new categories [32][33] - **Value Share Growth**: Reynolds has increased its total nicotine volume share by over 100 basis points from December 2024 to December 2025, with significant contributions from smokeless categories [33][34] Conclusion - **Sustainable Value Creation**: BAT is focused on delivering sustainable value while preparing for future growth through a balanced portfolio of combustibles and new categories [42][43] - **Future Outlook**: The company is well-positioned to lead in the U.S. nicotine market, leveraging its multi-category portfolio and commitment to innovation and regulatory engagement [43][44]

Core Insights - The tobacco sector is primarily represented by two industry leaders: Altria Group, Inc. and Philip Morris International Inc., each with distinct geographic focuses and strategies to adapt to the evolving nicotine landscape [1][2] Altria Group, Inc. (MO) - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into smoke-free alternatives like NJOY and oral nicotine products [2] - In 2025, Altria achieved a 4.4% increase in adjusted earnings per share and returned approximately $8 billion to shareholders through dividends and share repurchases, highlighting its strong cash-flow generation [3] - The smokeable products segment generated over $11 billion in adjusted operating income with margins expanding to 63.4%, demonstrating Altria's pricing power despite a 9.5% decline in domestic cigarette volumes [4][6] - Altria's smoke-free strategy is advancing, with on! brand shipment volumes rising 10.9% in 2025, and plans for a national rollout of on! PLUS to capture growth in the nicotine pouch category [5] - The long-term investment outlook for Altria is challenged by structural and regulatory headwinds, with ongoing volume declines in traditional cigarettes [6] Philip Morris International Inc. (PM) - Philip Morris is transitioning towards smoke-free products, with smoke-free offerings accounting for 41% of total net revenues and 42% of gross profit in Q3 2025, driven by strong performance from IQOS, ZYN, and VEEV [7][8] - The company reported a record quarterly smoke-free gross profit of $3.1 billion, indicating a shift towards a more sustainable profit model [7] - Philip Morris' operational discipline and productivity initiatives have supported margin expansion and earnings growth, despite a 3.2% decline in cigarette shipment volumes in Q3 [10][11] - The reliance on smoke-free products introduces risks, as any slowdown in adoption could impact the ability to offset declines in combustible product volumes [11] Stock Performance and Valuation - Over the past year, Altria's shares increased by 15.9%, underperforming Philip Morris, which surged by 36.5%, and the industry's growth of 38.7% [12] - Altria's forward P/E ratio is 10.7, slightly below its one-year median, while Philip Morris' forward P/E ratio stands at 21.12, above its median [13] - Philip Morris is viewed as a more promising investment due to its diversified international presence and established portfolio of reduced-risk products, while Altria's growth is limited by its heavy exposure to the U.S. cigarette market [16][17]

Core Insights - Philip Morris International Inc. (PM) is recognized as one of the 15 Best S&P 500 Dividend Stocks to Buy in 2026 [1] Group 1: Analyst Ratings and Market Position - Jefferies analyst Edward Mundy downgraded PM from Buy to Hold and reduced the price target from $220 to $180, citing limited re-rating potential for the stock in 2026 [2] - The analyst highlighted increased competition, particularly from British American Tobacco in US nicotine pouches and Japan Tobacco in heated tobacco, indicating potential downside risks to consensus estimates for PM [2] Group 2: Investment Commitments - PM has committed to investing over $20 billion in the US since 2022, primarily focused on enhancing manufacturing capabilities, commercial rights, and infrastructure, as well as supporting US jobs [3] - In 2022, approximately $19 billion of these investments were made, including the acquisition of Swedish Match, which generates most of its revenue in the US and is a key part of PM's US investment strategy [4] Group 3: Economic Impact and Job Creation - Since the acquisition of Swedish Match, PM has invested over $1 billion in American manufacturing and operational capabilities through September 30, 2025, with infrastructure projects in Colorado, Kentucky, and North Carolina [5] - These investments are projected to create over 1,000 direct jobs and 1,500 indirect jobs, with an estimated ongoing annual economic impact exceeding $800 million [5] Group 4: Company Overview - PM is a global consumer goods company focused on transitioning to a smoke-free future and evolving its portfolio beyond traditional tobacco and nicotine products [6]

Core Insights - Altria Group, Inc. has formed an alliance with KT&G to explore international opportunities in modern oral nicotine products, aiming to expand its market presence beyond the U.S. [1][9] - The collaboration includes Altria acquiring a stake in Another Snus Factory, enhancing its product offerings in regions with growing demand for complex flavor profiles [2] - The partnership allows Altria to utilize KT&G's global infrastructure and product development expertise while contributing its strengths in commercialization and brand management [3] - The alliance is a strategic move towards expanding Altria's presence in smoke-free categories globally, as the modern oral market is experiencing rapid growth [4] - Successful execution of this partnership is crucial for Altria to strengthen its position in next-generation products and work towards a smoke-free future [5] Competitive Landscape - Philip Morris International Inc. has established itself as a leader in the smoke-free transition, with smoke-free products contributing 41% of its net revenues in Q3 2025, and its nicotine pouch brand ZYN showing 39% growth [6] - Turning Point Brands, Inc. is also experiencing significant growth, with its Modern Oral portfolio representing nearly one-third of sales and revenues rising 31.2% year-over-year to $119 million in Q3 2025 [7] Financial Performance - Altria's shares have declined by 12.8% over the past month, compared to a 4% decline in the industry [8] - Altria trades at a forward price-to-earnings ratio of 10.46X, lower than the industry average of 14.07X [11] - The Zacks Consensus Estimate indicates year-over-year earnings growth of 6.1% for 2025 and 2.5% for 2026 [12]

Core Insights - Altria Group, Inc. and Philip Morris International Inc. are navigating a transforming tobacco market with distinct strategies, focusing on smoke-free alternatives and maintaining strong brand presence [1][2] Altria Group, Inc. - Altria's pricing power is a key factor in its financial resilience, with a 10% net price realization in smokeable products leading to a 4.2% increase in adjusted operating companies income (OCI) in Q2 2025 [6] - The oral tobacco segment, particularly the on! nicotine pouch brand, saw shipments rise 26.5% year over year, contributing to a 10.9% increase in adjusted OCI [7] - Adjusted earnings per share (EPS) increased 8.3% year over year to $1.44 in Q2 2025, with revenues net of excise taxes at $5.29 billion [8] - Marlboro maintains a 59.5% share in the premium category, showcasing Altria's strong market position and ability to adapt to a smoke-free future [10] Philip Morris International Inc. - Philip Morris's growth is driven by smoke-free products, which accounted for 41% of total net revenues and 42% of gross profit in Q3 2025 [11] - Shipments of IQOS, ZYN, and VEEV showed significant growth, with IQOS shipments up 15.5% to 41 billion units, maintaining a 76% global share in heated tobacco [12] - Adjusted operating income rose 12.4% to $4.7 billion, with adjusted EPS increasing 17.3% to $2.24, supported by strong performance in smoke-free products [13] - Despite a 3.2% decline in cigarette shipment volumes, Philip Morris managed a 4.3% increase in net revenues through pricing strategies [14] Market Performance - Altria's stock has gained 25.3% over the past year, outperforming Philip Morris's 13.1% increase and the broader S&P 500's 20.6% rise [21] - Altria is trading at a forward P/E ratio of 11.41, while Philip Morris's forward P/E ratio stands at 18.24 [20] Investment Outlook - Altria is positioned as a better investment for income-focused investors due to its attractive valuation, robust pricing power, and growing smoke-free momentum, while Philip Morris offers stronger global growth potential [22]

Core Insights - Philip Morris International (PM) reported third-quarter 2025 results that exceeded Zacks Consensus Estimates for both revenue and earnings, reflecting strong growth prospects despite a recent stock correction [1][2] Financial Performance - Adjusted earnings per share (EPS) for Q3 2025 was $2.24, a 17.3% increase year-over-year, surpassing the Zacks Consensus Estimate by 6.67% [3] - Net revenues reached $10.8 billion, marking a 9.4% increase on a reported basis and 5.9% on an organic basis compared to the same quarter last year, with a positive surprise of 1.32% against the consensus estimate of $10.7 billion [4] - Operating income for the quarter was $4.3 billion, reflecting a substantial increase of 16.7% from the previous year [4] Product Shipment and Growth - Total shipment volume of cigarettes and smoke-free products grew by 0.7% year-over-year to 204.9 billion units, driven by a 91.0% increase in E-vapor shipments and a 16.9% rise in Oral smoke-free products [5] - The smoke-free business accounted for 41% of total net revenues, up 2.9 percentage points from the previous year, with a year-over-year growth of 17.7% in its top line and a 19.5% increase in gross profits [6] Future Guidance - For 2025, PM anticipates adjusted EPS in the range of $7.46-$7.56, indicating a growth of 13.5-15.1% from the previous year [7] - The company expects net revenues to increase by 6-8% on an organic basis and operating income to grow by 10-11.5%, alongside a projected smoke-free product volume growth of 12% to 14% [8]

Core Insights - Altria Group, Inc. is focusing on a smoke-free future, with its on! nicotine pouches driving significant growth in the oral tobacco products segment, achieving a retail share of 8.7% in the U.S. [1][8] - The company reported a 26.5% increase in shipment volume, reaching 52.1 million cans in the second quarter of 2025, contributing to substantial profit growth [2][8] - Altria's strategy, executed through its subsidiary Helix, emphasizes aggressive brand-building and emotional connections with adult consumers to maintain momentum in a competitive market [3][4] Market Position and Competition - Philip Morris International Inc. is also advancing in the smoke-free product space, with these products accounting for 41% of total net revenues and over 42% of gross profit in the second quarter of 2025, showing 11.8% shipment growth [5] - Turning Point Brands, Inc. is emerging as a competitor, with its Modern Oral sales increasing nearly eightfold year-over-year to $30.1 million, representing 26% of total revenues [6] Financial Performance - Altria's shares have increased by 15.4% over the past three months, contrasting with a 4.3% decline in the industry [7] - The company trades at a forward price-to-earnings ratio of 12.05X, lower than the industry average of 14.27X [10] - Zacks Consensus Estimate indicates year-over-year earnings growth of 6.1% for 2025 and 2.6% for 2026 [11]

Core Points - Philip Morris International (PMI) U.S. announced a $37 million investment in its manufacturing facility in Wilson, North Carolina, aimed at expanding operations and supporting the company's mission to provide smoke-free alternatives to adult smokers [1][2] - The investment is part of PMI U.S.'s broader "Invested in America" platform, which focuses on increasing U.S. manufacturing and innovation capacity through strategic investments [1][5] - The Wilson facility currently employs over 80 full-time staff and produces HEETS for IQOS 3.0, the only heated tobacco product authorized by the FDA as a modified risk tobacco product [2][3] Investment and Economic Impact - The expansion in Wilson is expected to generate economic activity in the local community and reinforce PMI U.S.'s long-term commitment to American manufacturing [1][2] - PMI U.S. has previously invested hundreds of millions of dollars in U.S. manufacturing and innovation, including a $232 million expansion in Owensboro, Kentucky, and a $600 million investment in Aurora, Colorado, which together will create nearly 1,000 direct jobs [5] Product Development - The Wilson expansion will add a production line for TEREA, consumables for the IQOS ILUMA heated tobacco system, with premarket tobacco product applications submitted to the FDA on October 20, 2023 [4] - IQOS 3.0 is currently being commercialized in select locations, including Austin, Texas, and Jackson, Mississippi, as well as on military bases [4]

Core Insights - The tobacco sector presents two main investment options: Altria Group, Inc. and Philip Morris International Inc., each with distinct market strategies and growth trajectories towards a smoke-free future [1][2] Altria Group, Inc. - Altria focuses on the U.S. market, leveraging its Marlboro brand while expanding into alternatives like NJOY and oral nicotine pouches [2] - The company achieved a 10.8% net price realization in smokeable products in Q1 2025, contributing to a 2.7% increase in adjusted operating income [3][9] - Altria's oral nicotine pouch brand, on!, saw an 18% increase in shipments, capturing 8.8% of the oral tobacco category and 17.9% of the nicotine pouch segment [4][9] - Despite setbacks in the e-vapor category, Altria is refining its product pipeline and advocating for regulatory reforms to combat the rise of illicit disposable e-vapor products, which account for over 60% of the U.S. market [5] - The cigarette industry faces challenges, with shipment volumes declining due to macroeconomic pressures and the growth of illegal e-vapor products, impacting low-income smokers [6] Philip Morris International Inc. - Philip Morris is advancing its transformation strategy with a strong smoke-free portfolio, including IQOS, ZYN, and VEEV, and has approximately 41.5 million adult users by Q2 2025 [7][9] - IQOS is the primary driver of growth, with accelerated adoption in key markets supported by commercial initiatives and product innovations [8][10] - The company offers smoke-free products in 97 markets, with nearly half providing multiple product categories, enhancing its global reach [10] - Philip Morris faces challenges such as currency volatility and increasing regulatory risks, particularly regarding nicotine pouch marketing [11] Financial Performance and Valuation - Altria's forward P/E ratio is 10.96, appealing to income-focused investors, while Philip Morris has a higher multiple of 20.12, reflecting its global presence and momentum in smoke-free products [15] - Over the past month, Altria gained 2.1%, while Philip Morris dropped 11.6%, underperforming the S&P 500's 3.4% rise [14] Conclusion - Philip Morris is better positioned for long-term growth with its aggressive pivot towards a smoke-free future and strong global traction, while Altria's focus on domestic stability and pricing strength supports income-focused investors but faces more headwinds [16]